Is Adial Pharmaceuticals, Inc. (ADIL) a Buy, Sell, or Hold?
Adial Pharmaceuticals, Inc.
NASDAQ:ADIL
$2.65 USD
-$0.18 (-6.36%)
- Volume
- 65.86K
- Average Volume
- 479.39K
- Market Capitalization
- $2.54M
- P/E Ratio
- -0.27
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $19.00
- Year Low
- $1.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.18
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Cary John Claiborne |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADIL |
| CUSIP | 00688A304 |
| CIK | 0001513525 |
| Web | https://www.adial.com |
| Phone | 434 422 9800 |
| Currency | USD |
| Employees | 5 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.18 |
| Quick Ratio | 3.18 |
| Cash Ratio | 3.04 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -4.76 |
| Price / Cash Flow | -0.39 |
| Price / Book | 0.98 |
Price Target and Rating
| Average Stock Price Forecast | $7.00 |
| High Stock Price Forecast | $8.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -62.14% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-11.93 |
| Trailing P/E Ratio | -0.27 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-7.98M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -162.83% |
| Return on Assets | -148.66% |
Financials Score
| AltmanZ Score | -27.70 |
| Piotroski Score | 2.00 |
| Working Capital | 3.29M |
| Total Assets | 5.23M |
| Ebit | -7.77M |
| Market Cap | 2.73M |
| Total Liabilities | 1.51M |
Poll Results
About Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Stock
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia. ...
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
2026-06-16 08:00:00
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. (“Azora”), which was previously announced by the Company on June 11, 2026.
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
2026-06-11 11:43:00
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
2026-05-11 08:30:00
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2026 first quarter ended March 31, 2026.
2026-04-29 09:07:00
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach
2026-04-27 08:47:00
GLEN ALLEN, Va. , April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the submission of the AD04 product application for consideration of the Food and Drug Administration (FDA) Commissioner's National Priority Voucher Pilot Program (CNPV).
2026-04-27 08:47:00
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatments inadequately address patient outcomes Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatments inadequately address patient outcomes
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April
2026-04-26 03:13:06
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 49,013 shares, a decrease of 49.4% from the March 31st total of 96,887 shares. Currently, 3.5% of the company's stock are short sold.
2026-04-22 09:35:00
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product production
Frequently Asked Questions
-
What is the current Adial Pharmaceuticals, Inc. (ADIL) stock price?
-
Adial Pharmaceuticals, Inc.(NASDAQ:ADIL) stock price is $2.65 in the last trading session. During the trading session, ADIL stock reached the peak price of $19 while $1.31 was the lowest point it dropped to. The percentage change in ADIL stock occurred in the recent session was --6.36% while the dollar amount for the price change in ADIL stock was -$-0.18.
-
ADIL's industry and sector of operation?
-
The NASDAQ listed ADIL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADIL?
-
Tony Goodman | Chief Operating Officer & Director
Vinay Shah | Chief Financial Officer & Treasurer
Adam D. Cutler | Interim Executive Vice President of Finance & Business
Julie Saiki | Executive Vice President of Strategy
Matthew Davidson | Chief Development Officer & Director -
How many employees does ADIL have?
-
Number of ADIL employees currently stands at 5. ADIL operates from 1180 Seminole Trail, Charlottesville, VA 22901, US.
-
Link for ADIL official website?
-
Official Website of ADIL is: https://www.adial.com
-
How do I contact ADIL?
-
ADIL could be contacted at phone #434 422 9800 and can also be accessed through its website. ADIL operates from 1180 Seminole Trail, Charlottesville, VA 22901, US.
-
How many shares of ADIL are traded daily?
-
The average number of ADIL shares traded daily for last 3 months was 479.39K.
-
What is the market cap of ADIL currently?
-
The market value of ADIL currently stands at $2.54M with its latest stock price at $2.65